MX2013010770A - Tratamiento de tumores solidos. - Google Patents

Tratamiento de tumores solidos.

Info

Publication number
MX2013010770A
MX2013010770A MX2013010770A MX2013010770A MX2013010770A MX 2013010770 A MX2013010770 A MX 2013010770A MX 2013010770 A MX2013010770 A MX 2013010770A MX 2013010770 A MX2013010770 A MX 2013010770A MX 2013010770 A MX2013010770 A MX 2013010770A
Authority
MX
Mexico
Prior art keywords
inhibiting agent
iron chelator
autophagy inhibiting
chelator
optionally
Prior art date
Application number
MX2013010770A
Other languages
English (en)
Inventor
Stig Linder
Mårten Fryknäs
Rolf Larsson
Original Assignee
Vivolux Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivolux Ab filed Critical Vivolux Ab
Publication of MX2013010770A publication Critical patent/MX2013010770A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Un quelante de hierro permeable a células, opcionalmente en combinación con un agente inhibidor de la autofagia, se utiliza para el tratamiento de un tumor canceroso sólido en una persona. Un quelante preferido es una N-(1-piridín-2-il-metiliden)-N-(9H-1, 3,4,9-tetraazafluoren-2-il)-hidrazina sustituido por alquilo. Un agente inhibidor de la autofagia preferido es cloroquina. También se describe una composición farmacéutica que comprende quelante de hierro, portador farmacéuticamente aceptable y, opcionalmente, agente inhibidor de la autofagia; y un método de tratamiento del cáncer mediante la administración de cantidades efectivas para combatir el cáncer del quelante de hierro o de la combinación de agente quelante de hierro y agente inhibidor de la autofagia.
MX2013010770A 2011-03-21 2012-03-14 Tratamiento de tumores solidos. MX2013010770A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1100201 2011-03-21
PCT/SE2012/000034 WO2012128689A1 (en) 2011-03-21 2012-03-14 Treatment of solid tumours

Publications (1)

Publication Number Publication Date
MX2013010770A true MX2013010770A (es) 2014-03-27

Family

ID=46879602

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010770A MX2013010770A (es) 2011-03-21 2012-03-14 Tratamiento de tumores solidos.

Country Status (20)

Country Link
US (2) US20140073645A1 (es)
EP (1) EP2688569B1 (es)
JP (1) JP6064215B2 (es)
KR (1) KR101937279B1 (es)
CN (1) CN103547268B (es)
AU (1) AU2012231814B2 (es)
BR (1) BR112013024211B1 (es)
CA (1) CA2830081C (es)
DK (1) DK2688569T3 (es)
EA (1) EA025180B1 (es)
ES (1) ES2681703T3 (es)
HU (1) HUE039021T2 (es)
IL (1) IL228411A (es)
MX (1) MX2013010770A (es)
PL (1) PL2688569T3 (es)
PT (1) PT2688569T (es)
SG (2) SG10201605083SA (es)
TR (1) TR201809040T4 (es)
WO (1) WO2012128689A1 (es)
ZA (1) ZA201307036B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2900667B1 (en) * 2012-09-21 2019-06-05 Vivolux AB Means and method for treating solid tumours
US11504346B2 (en) 2013-11-03 2022-11-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Redox-activated pro-chelators
CN105807976B (zh) 2014-12-31 2019-02-12 清华大学 静电传感器
EP3283088A4 (en) * 2015-04-17 2018-10-24 Memorial Sloan-Kettering Cancer Center Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors
CN104997777A (zh) * 2015-07-24 2015-10-28 孔小乐 去铁酮的2比1锌络合物作为制备抗癌药物的应用
JP7103745B2 (ja) * 2015-10-05 2022-07-20 国立大学法人 岡山大学 癌幹細胞抑制剤、癌の転移又は再発の抑制剤並びに癌細胞の未分化マーカー発現抑制剤
AU2016371541B2 (en) 2015-12-18 2021-07-08 Vivolux Ab Pharmaceutical composition comprising indole derivatives, process for preparation and use thereof
EP3558282A4 (en) * 2016-12-21 2020-08-12 The Medical College of Wisconsin, Inc. SYNERGIC INHIBITION OF TUMOR CELL PROLIFERATION INDUCED BY A THERAPEUTIC ASSOCIATION OF METFORMIN COMPOUNDS AND IRON CHELATORS
WO2018147612A1 (ko) * 2017-02-07 2018-08-16 주식회사 온코크로스 암의 전이 억제 및 치료용 조성물
KR101859922B1 (ko) * 2017-02-07 2018-05-21 주식회사 온코크로스 클로페네신을 포함하는 대장암 증식 및 전이 억제용 조성물
CN106831776B (zh) * 2017-03-16 2018-12-07 河北科技大学 5,10-二氢吡啶并吡嗪并三嗪类化合物及其应用
EP3713573A1 (en) * 2017-11-23 2020-09-30 Deutsches Krebsforschungszentrum Iron chelators in tumor therapy
CN109646679A (zh) * 2019-01-28 2019-04-19 中国科学院长春应用化学研究所 铁离子螯合剂及其可药用盐的用途
CN110585194A (zh) * 2019-10-12 2019-12-20 广州医科大学附属第五医院 倍半萜内酯类化合物在制备溶酶体自噬抑制剂以及抗癌药物中的应用
CN111849873A (zh) * 2020-07-30 2020-10-30 扬州大学 一种诱导鸡的胚胎干细胞自噬的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335686C (fr) * 1986-01-13 1995-05-23 Rao K. S. P. Bhushana Vinblastine et composition pharmaceutique les contenant
US5480906A (en) * 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
IL121272A (en) * 1997-07-10 2000-06-01 Can Fite Technologies Ltd Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
US6660737B2 (en) * 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
CA2515027A1 (en) * 2003-02-05 2004-08-19 Unisearch Limited Metal ion chelators and therapeutic use thereof
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US20060128805A1 (en) * 2004-11-19 2006-06-15 Shah Sudhir V Methods of treating erythropoietin-resistance
CN101443002B (zh) * 2006-05-09 2012-03-21 诺瓦提斯公司 包含铁螯合剂和抗肿瘤药的组合及其用途
WO2009035534A2 (en) * 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
KR101208587B1 (ko) * 2009-06-24 2012-12-06 여오영 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
EP2900667B1 (en) 2012-09-21 2019-06-05 Vivolux AB Means and method for treating solid tumours

Also Published As

Publication number Publication date
ZA201307036B (en) 2014-05-28
PL2688569T3 (pl) 2018-09-28
EP2688569A4 (en) 2014-09-10
BR112013024211B1 (pt) 2020-12-15
CA2830081A1 (en) 2012-09-27
US20170348317A1 (en) 2017-12-07
CN103547268A (zh) 2014-01-29
DK2688569T3 (en) 2018-08-06
PT2688569T (pt) 2018-08-06
JP2014508804A (ja) 2014-04-10
WO2012128689A1 (en) 2012-09-27
IL228411A0 (en) 2013-12-31
EA025180B1 (ru) 2016-11-30
KR101937279B1 (ko) 2019-01-10
EP2688569B1 (en) 2018-05-30
TR201809040T4 (tr) 2018-07-23
CN103547268B (zh) 2017-02-22
US20140073645A1 (en) 2014-03-13
ES2681703T3 (es) 2018-09-14
SG193494A1 (en) 2013-10-30
BR112013024211A2 (pt) 2016-12-20
JP6064215B2 (ja) 2017-02-01
SG10201605083SA (en) 2016-08-30
CA2830081C (en) 2020-09-22
KR20140017619A (ko) 2014-02-11
IL228411A (en) 2016-12-29
US10022380B2 (en) 2018-07-17
AU2012231814A1 (en) 2013-09-26
EA201391286A1 (ru) 2014-03-31
AU2012231814B2 (en) 2016-06-09
HUE039021T2 (hu) 2018-12-28
EP2688569A1 (en) 2014-01-29

Similar Documents

Publication Publication Date Title
MX2013010770A (es) Tratamiento de tumores solidos.
PH12016502355A1 (en) Pharmaceutical composition
MY168791A (en) Carbamate compounds and of making and using same
GEP201706786B (en) Methods and drug products for treating alzheimer's disease
TR201807411T4 (tr) DNA-PK inhibitörleri.
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
WO2016133903A3 (en) Combination therapy for cancer treatment
HK1139863A1 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
MX2010010954A (es) Farmaco contra cancer de higado.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
NZ700761A (en) Salt form of a human histone methyltransferase ezh2 inhibitor
JO3776B1 (ar) التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf
SG10201811128RA (en) Ezh2 inhibitors for treating lymphoma
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
MX2014015986A (es) Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina.
RU2013148721A (ru) Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
PH12016502352A1 (en) Pharmaceutical composition
MX353964B (es) Agentes terapeuticos y usos de los mismos.

Legal Events

Date Code Title Description
FG Grant or registration